Cell Biology and Toxicology Клеточная биология

GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy

Lu, Li-Li, Xiao, Shu-xiu, Lin, Zhi-yuan, Bai, Jin-jin, Li, Wei, Song, Zheng-qing, Zhou, Yu-hong, Lu, Bin, Wu, Wei-Zhong
Springer Nature · 2023-12-01 · DOI 10.1007/s10565-023-09821-w

Аннотация

Background Chimeric antigen receptor (CAR)-T-cell therapy is a revolutionary treatment that has become a mainstay of advanced cancer treatment. Conventional glypican-3 (GPC3)-CAR-T cells have not produced ideal clinical outcomes in advanced hepatocellular carcinoma (HCC), and the mechanism is unclear. This study aims to investigate the clinical utility of novel GPC3-7–19-CAR-T cells constructed by our team and to explore the mechanisms underlying their antitumor effects. Methods We engineered a novel GPC3-targeting CAR including an anti-GPC3 scFv, CD3ζ, CD28 and 4-1BB that induces co-expression of IL-7 at a moderate level (500 pg/mL) and CCL19 at a high level (15000 pg /mL) and transduced it into human T cells. In vitro, cell killing efficacy was validated by the xCELLigence RTCA system, LDH nonradioactive cytotoxicity assay and was confirmed in primary HCC organoid models employing a 3D microfluid chip. In vivo , the antitumor capacity was assessed in a humanized NSG mouse xenograft model. Finally, we initiated a phase I clinical trial to evaluate the safety and effect of GPC3-7–19-CAR-T cells in the clinic. Results GPC3-7–19-CAR-T cells had 1.5–2 times higher killing efficiency than GPC3-CAR-T cells. The tumor formation rates in GPC3-7–19-CAR-T cells treated model were reduced (3/5vs.5/5), and the average tumor volumes were 0.74 cm^3 ± 1.17 vs. 0.34 cm^3 ± 0.25. Of note, increased proportion of CD4^+ T_EM and CD8^+ T_CM cells was infiltrated in GPC3-7–19-CAR-T cells group. GPC3-7–19-CAR-T cells obviously reversed the immunosuppressive tumor microenvironment (TME) by reducing polymorphonuclear (PMN)-myeloid-derived suppressor cells (MDSCs) and regulatory T (Treg) cells infiltration and recruiting more dendritic cells (DCs) to HCC xenograft tumor tissues. In one patient with advanced HCC, GPC3-7–19-CAR-T-cell treatment resulted in tumor reduction 56 days after intravenous infusion. Conclusions In conclusion, GPC3-7–19-CAR-T cells achieved antitumor effects superior to those of conventional GPC3-CAR-T cells by reconstructing the TME induced by the dominant CD4^+ T_EM and CD8^+ T_CM cell subsets. Most importantly, GPC3-7–19-CAR-T cells exhibited good safety and antitumor efficacy in HCC patients in the clinic. Graphical Abstract ► Novel GPC3-7-19-CAR-T cells designed with mediate level of IL-7 secretion and high level of CCL19 secretion, which could recruit more mature DCs to assist killing on GPC3^+HCCs. ►DC cells recruited by CCL19 could interact with CD4^+ T cells and promote the differentiation of CD4^+T_EFF cells into CD4^+T_EM and CD8^+T_CM subsets, leading a better anti-tumor effect on GPC3^+HCCs. ►Compared with conventional GPC3-CAR-T, GPC3-7-CCL19-CAR-T cells could reverse tumor immunosuppressive microenvironment by reducing PMN-MDSC and Treg cell infiltration.

Читать у издателя →